Table 1 Overall and chi-square test comparative demographic and clinical characteristics of the study patients
Characteristics | Overall cohort (n = 602) | Appropriate PI prescription (n = 103) | Inappropriate PI prescription (n = 499) | p-value |
|---|---|---|---|---|
Gender n (%) | ||||
 Female | 288 (47.8) | 43 (41.7) | 245 (49.1) | 0.174 |
Clinic level n (%) | 0.004 | |||
 Kampala City Council HIV Clinics | 104 (17.3) | 2 8 (26.9) | 76 (73.1) |  |
 Regional Referral HIV clinics | 498 (82.7) | 75 (15.1) | 423 (84.9) |  |
Age at start of TB treatment (years), median (IQR) | 35 (26–4) |  |  | 0.033 |
  < 25, n (%) | 131 (21.8) | 22 (16.8) | 109 (83.2) |  |
 25–34, n (%) | 165 (27.4) | 31 (18.8) | 134 (81.2) |  |
 35–44, n (%) | 179 (29.7) | 29 (16.2) | 150 (83.8) |  |
 45–54, n (%) | 100 (16.6) | 12 (12.0) | 88 (80.0) |  |
 55–64, n (%) | 22 (3.7) | 9 (40.9) | 13 (59.1) |  |
  > 64, n (%) | 5 (0.8) | 0 | 5 (100.0) |  |
Number of months on PI before TB therapy, median (IQR) | 7.15 (0.0–24.6) |  |  | 0.004 |
 PI and TB treatment started on the same date, n (%) | 185 (30.7) | 45 (43.7) | 140 (28.1) |  |
 0–6 months, n (%) | 106 (17.6) | 22 (21.4) | 84 (16.8) |  |
 7–12 months, n (%) | 56 (9.30) | 9 (8.7) | 47 (9.4) |  |
 13–24 months, n (%) | 102 (16.9) | 12 (11.7) | 90 (18.0) |  |
  > 24 months, n (%) | 153 (25.4) | 15 (14.6) | 138 (27.7) |  |
Weight at start of TB treatment (kg) n (%) | 0.022 | |||
  < 33 | 30 (5.0) | 8 (26.7) | 22 (73.3) |  |
 33–39 | 44 (7.3) | 9 (20.5) | 35 (79.6) |  |
 40–54 | 303 (50.3) | 44 (14.5) | 259 (85.5) |  |
 55–70 | 198 (32.9) | 32 (16.2) | 16 (83.8) |  |
  > 70 | 27 (4.5) | 10 (37.0) | 17 (63.0) |  |
Functional status at start of TB treatment n (%) | ||||
 Ambulatory | 91 (15.1) | 14 (15.4) | 77 (84.6) | 0.604 |
 Bedridden | 27 (4.5) | 4 (14.8) | 23 (85.2) |  |
 Working | 484 (80.4) | 85 (17.4) | 399 (82.6) |  |
Number of LFTs done during PI-TB treatment n (%) | ||||
 0 | 531 (88.2) | 99 (18.6) | 432 (81.4) | 0.006 |
  ≥ 1 | 71 (11.8) | 4 (5.6) | 67 (94.4) |  |
Reported ART adherence during TB treatment n (%) | ||||
  ≥ 95% | 459 (76.3) | 79 (17.2) | 380 (82.8) | 0.805 |
 85–94% | 50 (8.3) | 7 (14.0) | 43 (86.0) |  |
  < 85% | 93 (15.5) | 17 (18.3) | 76 (81.7) |  |